Coherus Oncology vs Gossamer Bio
Coherus Oncology and Gossamer Bio are similar in size: $42.2m and $48.5m of revenue in their latest fiscal years. Coherus Oncology grew faster (59.8% against -57.7%). Coherus Oncology kept more of each dollar of sales as profit: a net margin of 398.4% against -351.5%.
| Latest fiscal year | Coherus OncologyCHRS, 2025 | Gossamer BioGOSS, 2025 |
|---|---|---|
| Revenue | $42.2m | $48.5m |
| Revenue growth | 59.8% | -57.7% |
| Net income | $168m | −$170m |
| Operating margin | -429.5% | -352.2% |
| Net margin | 398.4% | -351.5% |
| Return on equity | — | — |
| Free cash flow | −$139m | −$171m |
| Cash | $88.9m | $37.7m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 147 | 161 |
| Market value | $116m | $4.62bn |
| Price vs our value range | — | — |
| Moat score | 19 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |